The SALL4 transcription factor is associated with embryonic cell pluripotency and has been shown as a useful immunohistochemical marker for germ cell tumors. However, information of SALL4 distribution in normal human tissues and non-germ cell tumors is limited. In this study we examined normal human tissues and 3215 tumors for SALL4 expression using a monoclonal antibody 6E3 and automated immunohistochemistry. In a 10-week embryo, SALL4 was expressed in ovocytes, intestine, kidney, and some hepatocytes. In adult tissues, it was only detected in germ cells. SALL4 was consistently expressed in all germ cell tumors except some trophoblastic tumors and mature components of teratomas, in which it was selectively expressed in intestinal-like and some squamous epithelia. In non-germ cell carcinomas, SALL4 was detected in 20% of cases or more of serous carcinoma of the ovary, urothelial high-grade carcinoma, and gastric adenocarcinoma (especially the intestinal type). SALL4 was only rarely (r5%) expressed in mammary, colorectal, prostatic, and squamous cell carcinomas. Many SALL4-positive carcinomas showed poorly differentiated patterns, and some showed positivity in most tumor cells mimicking the expression in germ cell tumors. SALL4 was commonly expressed in rhabdoid tumors of the kidney and extrarenal sites and in the Wilms tumor. Expression of SALL4 was rare in other mesenchymal and neuroendocrine tumors but was occasionally detected in melanoma, desmoplastic small round cell tumor, epithelioid sarcoma, and rhabdomyosarcoma. All hematopoietic tumors were negative. SALL4 is an excellent marker of nonteratomatous germ cell tumors, but it is also expressed in other tumors, sometimes extensively. Such expression may reflect stem cell-like differentiation and must be considered when using SALL4 as a marker for germ cell tumors. Observed lack of other pluripotency factors, OCT4 and NANOG, in SALL4-positive non-germ cell tumors can also be diagnostically helpful.
Abstract:
The SALL4 transcription factor is associated with embryonic cell pluripotency and has been shown as a useful immunohistochemical marker for germ cell tumors. However, information of SALL4 distribution in normal human tissues and non-germ cell tumors is limited. In this study we examined normal human tissues and 3215 tumors for SALL4 expression using a monoclonal antibody 6E3 and automated immunohistochemistry. In a 10-week embryo, SALL4 was expressed in ovocytes, intestine, kidney, and some hepatocytes. In adult tissues, it was only detected in germ cells. SALL4 was consistently expressed in all germ cell tumors except some trophoblastic tumors and mature components of teratomas, in which it was selectively expressed in intestinal-like and some squamous epithelia. In non-germ cell carcinomas, SALL4 was detected in 20% of cases or more of serous carcinoma of the ovary, urothelial high-grade carcinoma, and gastric adenocarcinoma (especially the intestinal type). SALL4 was only rarely (r5%) expressed in mammary, colorectal, prostatic, and squamous cell carcinomas. Many SALL4-positive carcinomas showed poorly differentiated patterns, and some showed positivity in most tumor cells mimicking the expression in germ cell tumors. SALL4 was commonly expressed in rhabdoid tumors of the kidney and extrarenal sites and in the Wilms tumor. Expression of SALL4 was rare in other mesenchymal and neuroendocrine tumors but was occasionally detected in melanoma, desmoplastic small round cell tumor, epithelioid sarcoma, and rhabdomyosarcoma. All hematopoietic tumors were negative. SALL4 is an excellent marker of nonteratomatous germ cell tumors, but it is also expressed in other tumors, sometimes extensively. Such expression may reflect stem cell-like differentiation and must be considered when using SALL4 as a marker for germ cell tumors. Observed lack of other pluripotency factors, OCT4 and NANOG, in SALL4-positive non-germ cell tumors can also be diagnostically helpful.
S al-like protein 4 (SALL4) is a zinc-finger transcription factor expressed in embryonic stem cells and important during embryonic development, as studied in murine embryos. 1 SALL4 is a master regulator of embryonal pluripotency and forms a regulatory network with other pluripotency-related transcription factors OCT4 (POU5F1) and NANOG. [2] [3] [4] SALL4 is important for early development, and homozygous loss-of-function mutants are embryo lethal. 5 Haploinsufficient true truncating heterozygous mutations cause Okihiro syndrome (closely related if not same as Duane-radial ray syndrome and acro-renal-ocular syndrome) associated with ray defects involving thumbs and other parts of the limbs, deficient eye movements, renal malformations, and deafness. 6, 7 In contrast, induced overexpression causes acute myeloid leukemia in mice indicating oncogenic potential. 8 Whereas SALL4 is highly expressed in the early embryo, the SALL4 gene is switched off during mouse development, remaining expressed into adulthood only in germ cells. 9 Although known to be expressed in adult germ cells such as ovocytes 10 and spermatogonia, 11 its distribution in human tissues is incompletely characterized. Immunohistochemical detection of SALL4 protein has been suggested useful in the detection of germ cell tumors of the testis, ovary, mediastinum, and at metastatic sites. [11] [12] [13] [14] However, only small numbers of non-germ cell tumors were evaluated in these studies.
SALL4 has also been detected in some non-germ cell carcinomas, such as subsets of gastric carcinomas, 15 but many studies on carcinomas have been based on RNA expression and not on tissue immunohistochemistry. 16, 17 In this study, we systematically evaluated human normal tissues and 3215 epithelial, mesenchymal, neuroectodermal, and hematolymphoid neoplasms to determine the tissue distribution of SALL4 and evaluated its specificity for germ cell tumors. SALL4-positive tumors were further evaluated with 2 other pluripotency markers: OCT4 and NANOG.
MATERIALS AND METHODS
Normal tissues and the 3215 tumors were derived from surgical specimens. The tumors analyzed in this study were arranged in handmade multitumor blocks containing 30 to 60 tumors each, as previously described. 18 Various tumors used for this study were extensively immunohistochemically characterized.
Immunohistochemical staining starting from deparaffinization and ending with hematoxylin counterstaining was performed in a Leica Bond automated immunostainer. The mouse monoclonal antibody to SALL4 (clone 6E3) was obtained from Biocare Medical (Concord, CA) and diluted to 1:200. Mouse monoclonal antibody OCT3/4 (clone N1NK) was obtained from Novocastra/Leica (Bannockburn, IL) and diluted to 
RESULTS

Normal Tissues
In a 10-week-old fetus, SALL4-positive elements included germ cells of a gonad (probably ovary) that were strongly positive, primitive renal tubules, early glomerular epithelia, intestinal epithelia, and approximately 25% of hepatocytes. The latter showed weaker yet still distinct positivity. Skin, mesothelia, and all mesenchymal and neural tissues (brain, spinal cord) were negative ( Fig. 1) .
In normal adult tissues, positivity was detected only in germ cells (spermatogonia of testis), whereas skin, breast, salivary gland, respiratory and gastrointestinal epithelia, liver, pancreas, prostate, endometrium, thyroid, and squamous epithelia of the oral region were negative, as were mesenchymal, neural, and lymphoid tissues.
Germ Cell Tumors
SALL4 expression in germ cell tumors is shown in Table 1 . All seminomas (n = 85) were strongly and nearly uniformly positive ( Fig. 2A) , except 1 tumor, which was focally positive (10% of tumor cells). All embryonal carcinomas (n = 30) and yolk sac tumors (n = 9) or such components in combined tumors were strongly positive with practically uniform nuclear staining (Fig. 2B ). Trophoblastic components of testicular germ cell tumors (n = 4) and uterine choriocarcinomas (n = 3) also contained positive cells, but the positivity varied so that larger cells including the syncytiotrophoblastic elements were typically negative (Fig. 2C) . One testicular choriocarcinoma and 1 placental site trophoblastic tumor were entirely negative.
In differentiated components of testicular teratomas (all adult patients), the SALL4 positivity varied. In all, 6/10 cases contained positive cells, often in low numbers. Positive elements included mature-appearing intestinal goblet cell-containing epithelia and isolated squamous epithelial cells (Fig. 2D) . Stromal connective tissues, smooth muscle, and cartilage were negative.
Non-Germ Cell Carcinomas
Expression of SALL4 in epithelial neoplasms is summarized in Table 1 . Ovarian serous carcinoma had the highest frequency of SALL4-positive cases among any specific non-germ cell carcinoma (23/78, 29%). Although most of the positive cases were high-grade carcinomas, a serous tumor of low malignant potential was also positive with extensive staining of the epithelia (Fig. 3A) . The percentage of SALL4-positive cells varied from 5% to 70% (median, 20%). Five cases had 50% or more (Fig. 3B) .
Endometrial carcinomas were SALL4 positive in 8/114 cases (7%). One of these cases was a mismatch repair-deficient tumor (MLH1 À , PMS2 À ). All positive examples were high-grade tumors often showing rudimentary, if any, glandular differentiation (Fig. 3C) . In 1 case, sarcomatoid stroma was positive and glandular elements negative (Fig. 3D) .
Gastric adenocarcinomas showed SALL4-positive cells in 24/102 cases (24%). The percentage of positive cells varied from 3% to 100% (median, 25%). A great majority of positive tumors had intestinal-like differentiation (Fig. 4A) and at least focally expressed CDX2 (19/24) and keratin 20 (19/23) . One hepatoid carcinoma (Fig. 4B) was also strongly SALL4 positive (100%), whereas diffuse signet ring cell carcinomas were only rarely positive (1/22) .
Pancreatic adenocarcinomas contained SALL4-positive cells in 7/93 cases (8%). Four moderately differentiated gland-forming tumors had 5% to 20% positive cells, and 3 poorly differentiated tumors forming solid sheets, including 1 sarcomatoid example, had 20%, 50%, and 100% positive tumor cells (Fig. 4C) .
Colorectal adenocarcinomas were only rarely positive (9/305, 3%). The number of positive cells varied from 5% to 100% (median, 28%). Of the positive cases, 3 were liver metastases, and they had 5%, 60%, and 100% of tumor cells positive. Only 1 of the positive cases was mismatch repair deficient (negative for MLH1 and PMS2).
Pulmonary adenocarcinomas contained SALL4-positive cells in 8/140 cases (6%), often in large numbers (Fig. 4D) . Most examples were poorly differentiated tumors, and the content of positive cells varied from 10% to 100% (median, 75%). Pulmonary small cell carcinomas contained SALL4-positive cells in 5/26 cases (19%), with 5% to 30% of tumor cells positive (median, 5%).
Mammary ductal carcinomas were only rarely SALL4 positive (5/208, 2%). Two cases contained 5% and 2 had 20% of positive nuclei, and in 1 case all tumor cell nuclei were positive. Four of these cases were positive for estrogen receptor and also strongly positive (3+) for HER2 with uniform membrane labeling, whereas 1 case was triple negative (ER À , PR À , HER2 À ). All lobular carcinomas were negative.
Renal carcinomas of the common types were uniformly negative. Squamous cell carcinomas of different locations all showed a low frequency of SALL4 expression detected in <5% of cases in each category. All positive examples were poorly differentiated, nonkeratinizing squamous cell carcinomas.
Metastatic carcinomas of unknown origin showed the highest frequency of any non-germ cell tumor (5/16, 31%). These keratin-positive tumors were composed of solid sheets of cohesive epithelial cells without gland formation. One case was also positive for OCT4 (a possible germ cell tumor). These tumors lacked "organ-specific" markers such as TTF1, CDX2, and GATA3.
A representative number of SALL4-positive nongerm cell epithelial neoplasms examined for OCT4 (n = 80) and NANOG (n = 76) were all negative. Whereas OCT4 was also negative for cytoplasmic staining, several cases showed variable, often strong, cytoplasmic NANOG positivity without nuclear immunoreactivity.
Nonepithelial and Unclassified Neoplasms
A renal rhabdoid tumor from a 27-year-old man had 30% positive tumor cells. This tumor was also INI1 deficient (Fig. 5) . Two extrarenal rhabdoid tumors in children were similarly SALL4 positive. Wilms tumors were variably SALL4 positive. In some cases, only tubular elements were positive (Figs. 6A, B) , whereas in some "triphasic" examples, the positivity was restricted to blastema, with epithelial tubules and stroma being negative (Figs. 6C, D; Table 2 ).
Other mesenchymal, neuroectodermal, and lymphoid tumors were almost uniformly negative for SALL4 (Table 2 ). However, 2 metastatic malignant melanomas (3% of all cases), both positive for S100 protein and at least focally for HMB45 and MelanA, contained 50% and nearly 100% of SALL4-positive tumor cells, respectively (Fig. 7A) . One desmoplastic small round cell tumor positive for keratins and desmin was also extensively SALL4 positive (Fig. 7B) , as was an embryonal rhabdomyosarcoma of the uterine cervix (Fig. 7C ) and an epithelioid sarcoma (Fig. 7D ).
DISCUSSION
In this study, we examined the expression of SALL4, a pluripotency-related transcription factor in normal and neoplastic human tissues, to determine its specificity for germ cell tumors and discover possible non-germ cell targets for diagnostic immunohistochemistry.
SALL4 is expressed in germ cells and is an excellent marker for malignant germ cell tumors in that most of these tumors are strongly and uniformly positive, a feature less commonly found in non-germ cell tumors.
In our study, seminomas, embryonal carcinomas, and yolk sac tumors were equally positive, as previously reported. [10] [11] [12] [13] [14] However, SALL4 does not seem to be expressed in all trophoblastic tumors in our relatively small sample. Although it is at least focally detected in all choriocarcinomas, it is absent in larger, perhaps more differentiated, cells, especially in syncytiotrophoblasts. Therefore, negative results do not necessarily rule out trophoblastic differentiation.
Differentiated components (studied here in adult testicular germ cell tumors) showed limited SALL4 positivity indicating that SALL4 is no longer present during somatic differentiation. The teratoma components that were exceptionally positive include intestinal-like epithelia, and this mirrors the fetal SALL4 expression in intestinal epithelia. Absence of SALL4 in many germ cell tumor elements with somatic differentiation also indicates that this marker may not be able to detect somatic derivatives of germ cell tumors, such as squamous cell carcinomas originating from teratomas.
On the basis of our observations, SALL4 is by no means specific for germ cell tumors. It is expressed in diverse types of carcinomas, although more commonly only focally in this context. The non-germ cell tumors showing highest percentages of cases with SALL4 expression (close to 20% or more) were ovarian serous carcinoma, gastric adenocarcinoma, hepatic cholangiocarcinoma, pulmonary small cell carcinoma, and urothelial carcinoma. In many carcinoma categories, SALL4 positivity had predilection to poorly differentiated tumors, such as carcinomas with solid undifferentiated patterns, with SALL4 positivity often correlating with a low level of differentiation apparently reflecting a stem cell-like phenotype. Whether SALL4 expression in non-germ cell tumors has any clinical significance in terms of prognosis or chemotherapeutic response requires further study.
Gastric intestinal-type carcinomas (most of them shown here as CDX2 and CK20 positive) seem to be among the most commonly positive carcinomas often showing extensive SALL4 positivity. In their SALL4 positivity, they resemble early embryonic intestinal epithelia. A previous study reported SALL4 expression in 15% of gastric carcinomas with predilection to tumors with intestinal differentiation and often associated with synchronous liver metastases. 15 However, for some reason, colorectal carcinomas, also of intestinal phenotype, were only rarely SALL4 positive, indicating that, for SALL4, they do not have a fetal intestinal phenotype. The finding that many SALL4-positive colon carcinomas were metastatic suggests the possibility that SALL4-positive cells may be enriched in the case of metastases, possibly induced or selected by chemotherapy.
For SALL4 expression in non-germ cell tumors, our results differ from some previous studies that were based on relatively small numbers of cases. One study found that all ovarian serous carcinomas were SALL4 negative (0/23). 10 Another study reported all 12 lung cancers and 8 breast cancers negative for SALL4, while noting weak SALL4 expression in 6/18 gastric adenocarcinomas in up 20% to 25% of tumor cells. 14 Both of these studies used the same antibody clone as in our study but from a different source. However, use of a different detection system may be the source of the variance of results.
Because a small number of cases in many carcinoma categories had extensive SALL4 positivity in virtually all tumor cells, similar to that seen in germ cell tumors, even extensive SALL4 positivity cannot be considered specific for germ cell tumors. SALL4 positivity in pelvic tumors such as ovarian and urothelial carcinomas is especially significant for the differential diagnosis with germ cell tumors. There is no information on SALL4 in ovarian serous carcinomas or urothelial carcinomas. However, SALL4 expression in urothelial carcinomas may reflect oncofetal expression, as SALL4 is transiently expressed in the ureteric bud. 19 In ductal carcinomas of the breast, SALL4 was only rarely expressed (2%) but when present had a predilection to estrogen receptor-positive and strongly HER2-positive cases, which constituted 80% of positive ductal carcinomas (one was a triple negative tumor). As HER2 may be selectively expressed in cancer stem cell populations in ductal carcinomas, 20 SALL4 expression in HER2 + cancers may further define a subset of ductal carcinomas rich in stem cells. Possible clinical and oncologic correlation to SALL4 expression in ductal carcinomas of the breast requires further study. There are only scant observations on SALL4 in breast cancer, all based on mRNA expression studies. One study reported elevated SALL4 mRNA in 86% of breast cancers. 21 Compared with this, immunohistochemically detected expression is markedly more infrequent. In this study, SALL4 was not detected in hepatocellular carcinomas beyond expression in isolated cells, which was not considered positive as nuclear staining in sporadic cells can be potentially obtained with the epitope retrieval only. Whereas 2 previous studies also reported the absence of SALL4 expression in hepatocellular carcinoma contrasting gastric hepatoid carcinoma, 15, 22 a third study showed common SALL4 expression in hepatocellular carcinoma, although often in a clump-like nuclear pattern and usually limited to focal areas. 23 In general, SALL4 was only rarely expressed in mesenchymal and neuroectodermal tumors. However, 2 notable exceptions were rhabdoid tumors (renal and extrarenal) and Wilms tumors, a majority of which contained SALL4-positive components, although unpredictably in terms of epithelial versus stromal expression. Previous studies have detected SALL4 in both of these tumors. [24] [25] [26] The apparent rarity of SALL4 expression in epithelioid sarcoma suggests that this feature may distinguish epithelioid sarcoma from rhabdoid tumor, which has overlapping features in morphology as well as loss of INI1/SMARCB1 protein.
Among the other exceptional SALL4-positive mesenchymal or neuroectodermal tumors were 2 melanomas (3%), 1 desmoplastic small round cell tumor (8%), 1 embryonal rhabdomyosarcoma (2%), and 1 epithelioid sarcoma (5%) indicating rare and sporadic immunohistochemical expression of SALL4 in these tumors. Some of these tumors could clinicopathologically mimic germ cell tumors, for example, paratesticular rhabdomyosarcomas. Notably, SALL4-positive non-germ cell carcinomas or the rare SALL4-positive mesenchymal or neuroectodermal tumors were negative for OCT3/4 and NANOG, 2 other pluripotency markers indicating that secondary testing with those 2 antibodies may help evaluate germ cell versus non-germ cell origin of SALL4-positive tumors of unknown lineage.
However, in the context of germ cell tumors, one has to consider that many nonseminomatous germ cell tumors, such as yolk sac and trophoblastic tumors, are negative for OCT3/4 and NANOG so that SALL4 is the only positive marker of these 3 germ cell/pluripotency markers. 12 Therefore, additional markers may be necessary to distinguish yolk sac tumor from SALL4-positive non-germ cell carcinomas, especially the histologic and clinicopathologic mimics, such as ovarian carcinomas. Glypican-3 has been shown to be useful in this respect on the basis of one study that found nearly all ovarian serous and mucinous carcinomas to be negative except yolk sac tumors, which were positive. However, 17% of clear cell carcinomas had at least some glypican-3 positivity in one study. 27 Another study found an even higher percentage (44%) of clear cell carcinomas to be glypican-3 positive. 28 These observations indicate some immunohistochemical overlap in the antigen patterns of yolk sac tumor and clear cell carcinoma, so that careful morphologic observation and additional criteria are needed for their separation.
SALL4 has also been reported as expressed and pathogenetically important in acute myeloid leukemia and has therefore been considered an oncogene in this context. 8 Its expression has also been reported in various lymphomas, multiple myeloma, and acute lymphoblastic leukemia at the mRNA level. 29 Our immunohistochemical studies on myeloid sarcomas (tissue equivalent of acute myeloid leukemia) and various lymphomas failed to detect expression by immunohistochemistry. This suggests that expression of SALL4 protein in these tumors must be lower than that present in germ cell tumors and SALL4-positive non-germ cell carcinomas. However, lack of immunohistochemically detected expression may not necessarily rule out the biological role of SALL4 in hematopoietic/lymphoid tumors.
In conclusion, we examined >3000 human tumors for SALL4, a pluripotency and germ cell marker. In addition to its nearly consistent expression in germ cell tumors, SALL4 is frequently expressed in ovarian serous, urothelial, gastric intestinal carcinomas, cholangiocarcinomas, and small cell carcinomas, and sometimes in a majority of tumor cells, similar to germ cell tumors. In addition, other sporadic carcinomas, melanomas, and sarcomas can also be positive. This non-germ cell tumor expression of SALL4 may reflect a stem celllike phenotype of positive tumors and has to be considered when using SALL4 as a marker to evaluate possible germ cell differentiation. Clinical correlation of SALL4 expression in non-germ cell tumors should be further studied in terms of possible significance for prognosis and chemotherapeutic response. 
